Floatz logo

ANTI-CD22/PBD ADC ADCT-602

CD22 Positive

M.D. Anderson Cancer Centerantibody_drug_conjugatePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the CD22 Positive cohort.

Asset / SponsorPhaseRating
Inotuzumab Ozogamicin
Roswell Park Cancer Institute
Phase 2BB
Bosutinib
M.D. Anderson Cancer Center
Phase 1/2CCC
(+)-VINCRISTINE
Roswell Park Cancer Institute
Phase 1/2CCC
Fludarabine
M.D. Anderson Cancer Center
Phase 1/2CCC
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 1/2CCC
Autologous Humanized Anti-Cd22 Chimeric Antigen Receptor T Cells
M.D. Anderson Cancer Center
Phase 1/2CCC
Autologous Cd19/Cd22 Chimeric Antigen Receptor T-Cells
M.D. Anderson Cancer Center
Phase 1/2CCC

Same molecule, other indications

ANTI-CD22/PBD ADC ADCT-602 is also rated in:

myelodysplastic syndrome with excess blastsDormant
CCC
Indicative ·
48 / 100
View asset →
Philadelphia Chromosome PositiveDormant
CC
Indicative ·
47 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →